Why Is PSMA a Key Phenotypic Biomarker in Advanced Prostate Cancer?
Advanced Accelerator Applications | The Prostate Cancer Clinical Masterclass Series
Fortgeschrittenes PCA: Studie zur Therapie mit 177Lu-PSMA-617
![Biomedicines | Free Full-Text | Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis](https://www.mdpi.com/biomedicines/biomedicines-10-01575/article_deploy/html/images/biomedicines-10-01575-g002-550.jpg "Biomedicines | Free Full-Text | Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis")
Biomedicines | Free Full-Text | Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis
Cancers | Free Full-Text | Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease | Journal of Nuclear Medicine
![PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis | European Journal of Nuclear Medicine and Molecular Imaging](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00259-020-05040-1/MediaObjects/259_2020_5040_Fig1_HTML.png "PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis | European Journal of Nuclear Medicine and Molecular Imaging")
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis | European Journal of Nuclear Medicine and Molecular Imaging
Circulating androgen receptor gene amplification and resistance to 177Lu- PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial | British Journal of Cancer
PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy - ScienceDirect
Key Prospective Clinical Trials of PSMA-Targeting Radionuclides in... | Download Scientific Diagram
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James
PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy - ScienceDirect
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 | European Journal of Nuclear Medicine and Molecular Imaging
![Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial) | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-023-10725-5/MediaObjects/12885_2023_10725_Fig1_HTML.png "Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial) | BMC Cancer | Full Text")
Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial) | BMC Cancer | Full Text
PSMA PET/CT und PET/MRT in der Diagnostik des Prostatakarzinoms • Fachportal für Wehrmedizin & Wehrpharmazie
![Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer | EJNMMI Research | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13550-023-01033-x/MediaObjects/13550_2023_1033_Fig1_HTML.jpg "Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer | EJNMMI Research | Full Text")
Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer | EJNMMI Research | Full Text
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
![Frontiers | AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)](https://www.frontiersin.org/files/Articles/1059122/fmed-09-1059122-HTML-r1/image_m/fmed-09-1059122-g001.jpg "Frontiers | AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)")
Frontiers | AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
History of PSMA Power Technology Roadmap: from AAA TripTik® to Google Maps® - Ritu Sodhi - APEC | IEEETV
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review - Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James
![177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - The Lancet](https://www.thelancet.com/cms/attachment/14225012-ffb5-48bd-ac5a-4468b251c769/gr1.gif "177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - The Lancet")
177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial - The Lancet
Pharmaceutics | Free Full-Text | Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
![PDF] Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5818ab72f095addb203c1f123e850b902a52d548/4-Table3-1.png "PDF] Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer | Semantic Scholar")